Pascal Poignard
Overview
Explore the profile of Pascal Poignard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
10864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amen A, Yoo R, Fabra-Garcia A, Bolscher J, Stone W, Bally I, et al.
Elife
. 2025 Jan;
13.
PMID: 39817720
Circulating sexual stages of ) can be transmitted from humans to mosquitoes, thereby furthering the spread of malaria in the population. It is well established that antibodies can efficiently block...
2.
Depery L, Bally I, Amen A, Nemoz B, Buisson M, Grossi L, et al.
Microbiol Spectr
. 2024 Nov;
13(1):e0156824.
PMID: 39565133
Importance: Anti-SARS-CoV-2 serology was developed in 2020 in response to the COVID-19 pandemic to diagnose SARS-CoV-2 infection and monitor an individual's immunity following natural infection or vaccination. Given the relationship...
3.
Beaulieu M, Gaymard A, Massonnaud C, Peiffer-Smadja N, Bouscambert-Duchamp M, Carcelain G, et al.
J Antimicrob Chemother
. 2024 Sep;
79(11):2887-2895.
PMID: 39236218
Background: The antiviral efficacy of Evusheld (AZD7442) in patients hospitalized for SARS-CoV-2 is unknown. Methods: We analysed the evolution of both the nasopharyngeal viral load and the serum neutralization activity...
4.
Bally I, Drumont G, Rossi V, Guseva S, Botova M, Reiser J, et al.
Front Immunol
. 2024 Jun;
15:1419165.
PMID: 38911852
Complement activation is considered to contribute to the pathogenesis of severe SARS-CoV-2 infection, mainly by generating potent immune effector mechanisms including a strong inflammatory response. Involvement of the lectin complement...
5.
Hites M, Massonnaud C, Larranaga Lapique E, Belhadi D, Jamard S, Goehringer F, et al.
J Infect
. 2024 Feb;
88(3):106120.
PMID: 38367705
No abstract available.
6.
Amen A, Yoo R, Fabra-Garcia A, Bolscher J, Stone W, Bally I, et al.
bioRxiv
. 2023 Nov;
PMID: 37961136
Impact Statement: A naturally acquired human monoclonal antibody recognizes proteins expressed at different stages of the lifecycle through affinity-matured homotypic interactions with glutamate-rich repeats.
7.
Joyce C, Murrell S, Murrell B, Omorodion O, Ver L, Carrico N, et al.
PLoS Pathog
. 2023 Jun;
19(6):e1011416.
PMID: 37384622
Vaccination strategies aimed at maturing broadly neutralizing antibodies (bnAbs) from naïve precursors are hindered by unusual features that characterize these Abs, including insertions and deletions (indels). Longitudinal studies of natural...
8.
Clavarino G, Leroy C, Epaulard O, Raskovalova T, Vilotitch A, Pernollet M, et al.
Front Immunol
. 2022 Aug;
13:889813.
PMID: 35911748
COVID-19 is caused by the human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in widespread morbidity and mortality. CD4 T cells, CD8 T cells and neutralizing...
9.
Sulbaran G, Maisonnasse P, Amen A, Effantin G, Guilligay D, Dereuddre-Bosquet N, et al.
Cell Rep Med
. 2022 Mar;
3(2):100528.
PMID: 35233549
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused an ongoing global health crisis. Here, we present as a vaccine candidate synthetic SARS-CoV-2 spike (S) glycoprotein-coated lipid vesicles...
10.
Chabert C, Vitte A, Iuso D, Chuffart F, Trocme C, Buisson M, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163833
Preventing the cytokine storm observed in COVID-19 is a crucial goal for reducing the occurrence of severe acute respiratory failure and improving outcomes. Here, we identify Aldo-Keto Reductase 1B10 (AKR1B10)...